Black Diamond Therapeutics Inc (NASDAQ: BDTX) on Monday, plunged -6.49% from the previous trading day, before settling in for the closing price of $2.62. Within the past 52 weeks, BDTX’s price has moved between $1.91 and $7.66.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 30.85%. With a float of $42.91 million, this company’s outstanding shares have now reached $56.52 million.
Let’s determine the extent of company efficiency that accounts for 54 employees. In terms of profitability, gross margin is 92.97%, operating margin of -1662.46%, and the pretax margin is -1493.65%.
Black Diamond Therapeutics Inc (BDTX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Black Diamond Therapeutics Inc is 24.16%, while institutional ownership is 75.23%. The most recent insider transaction that took place on Aug 28 ’24, was worth 1,400,556. In this transaction 10% Owner of this company sold 221,600 shares at a rate of $6.32, taking the stock ownership to the 3,726,341 shares. Before that another transaction happened on Jul 31 ’24, when Company’s Former Employer proposed sale 50,000 for $6.20, making the entire transaction worth $310,000.
Black Diamond Therapeutics Inc (BDTX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.33 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 30.85% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.01% during the next five years compared to -49.79% drop over the previous five years of trading.
Black Diamond Therapeutics Inc (NASDAQ: BDTX) Trading Performance Indicators
Black Diamond Therapeutics Inc (BDTX) is currently performing well based on its current performance indicators. A quick ratio of 5.55 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.36, a number that is poised to hit -0.31 in the next quarter and is forecasted to reach -1.22 in one year’s time.
Technical Analysis of Black Diamond Therapeutics Inc (BDTX)
Looking closely at Black Diamond Therapeutics Inc (NASDAQ: BDTX), its last 5-days average volume was 0.7 million, which is a drop from its year-to-date volume of 1.33 million. As of the previous 9 days, the stock’s Stochastic %D was 59.84%. Additionally, its Average True Range was 0.22.
During the past 100 days, Black Diamond Therapeutics Inc’s (BDTX) raw stochastic average was set at 12.22%, which indicates a significant decrease from 53.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 84.57% in the past 14 days, which was higher than the 76.23% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.37, while its 200-day Moving Average is $4.28. However, in the short run, Black Diamond Therapeutics Inc’s stock first resistance to watch stands at $2.55. Second resistance stands at $2.65. The third major resistance level sits at $2.75. If the price goes on to break the first support level at $2.35, it is likely to go to the next support level at $2.25. Now, if the price goes above the second support level, the third support stands at $2.15.
Black Diamond Therapeutics Inc (NASDAQ: BDTX) Key Stats
Market capitalization of the company is 138.63 million based on 56,585K outstanding shares. Right now, sales total 0 K and income totals -82,440 K. The company made 0 K in profit during its latest quarter, and -15,560 K in sales during its previous quarter.
